Patterson-UTI (PTEN) Receives a Buy from Stifel Nicolaus
In a report released yesterday, Stephen Gengaro from Stifel Nicolaus maintained a Buy rating on Patterson-UTI, with a price target of $15.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Gengaro covers the Energy sector, focusing on stocks such as Patterson-UTI, Schlumberger, and Cactus. According to TipRanks, Gengaro has an average return of 25.8% and a 57.92% success rate on recommended stocks.
Patterson-UTI has an analyst consensus of Moderate Buy, with a price target consensus of $12.86.
Based on Patterson-UTI’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.12 billion and a GAAP net loss of $24.63 million. In comparison, last year the company earned a revenue of $1.28 billion and had a net profit of $1.01 million
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTEN in relation to earlier this year. Earlier this month, Forrest C Robinson, the CAO of PTEN sold 19,419.00 shares for a total of $232,589.80.
Read More on PTEN:
Disclaimer & DisclosureReport an Issue
- Patterson-UTI price target raised to $15 from $14 at Stifel
- Patterson-UTI Expands Equity Plan and Refinances Senior Notes
- Patterson-UTI price target lowered to $13 from $23 at Goldman Sachs
- Patterson-UTI price target raised to $15 from $14 at RBC Capital
- Patterson-UTI price target raised to $14 from $13 at Susquehanna
